Clinical significance of FAM19A4 gene promotor methylation in cervical cancer
10.3969/j.issn.1006-5725.2018.09.033
- VernacularTitle:FAM19A4基因启动子甲基化检测在宫颈癌组织中的临床意义
- Author:
Qiaowen BU
1
;
Liang ZHANG
;
Sanfeng WANG
;
Jian MA
;
Guiying HU
;
Hengying WU
;
Xiping LUO
Author Information
1. 广州医科大学附属广东省妇幼保健院妇科 广州 510010
- Keywords:
cervical cancer;
FAM19A4;
DNA methylation;
quantitative PCR(qPCR)
- From:
The Journal of Practical Medicine
2018;34(9):1541-1544,1553
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of FAM19A4 gene promotor methylation in different cervical lesions and its diagnostic value. Methods 31 cervical cancers cases ,22 HSILs and 23 normal cervical tissues of formalin-fixed and parrffin-embedded specimen diagnosed by pathology were selected. Taqman probe-based quantitative PCR(qPCR)was used to detect the differences of FAM19A4 methylation in different cervical lesions, and then corresponding analyses were made. Results Statistical differences of FAM19A4 methylationrates were observed in cervical caner ,HSIL and normalcervix,respectively96.8%(30/31),72.7%(16/22)and 8.7%(2/23) (P < 0.05 ).FAM19A4 methylation rates increased with severity of cervical lesion (P < 0.05).The methylation rates of FAM19A4 were not statistically different in different clinicopathological characteristics of cervical cancer (P>0.05). Conclusions FAM19A4 gene promoter methylation is probably a specific biomarker of cervical cancer,andmay play a role in the development and progress of cervical cancer,but may not participate in the invasion and metastasis.
